Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center

Leukemia & lymphoma/Leukemia and lymphoma 2026

View at publisher
Authors: Hua‐Jay J. Cherng, David DeStephano, Patrick Gould, David Sabatino, Alexander D. Sanjurjo, Brian Cuzzo, Drew Gerber, Saagar Jain, Gaston Jean-Louis, KA Bhatt, Benjamin May, Craig Soderquist
+8 more Bachir Alobeid, J. Kahn, Ahmed Sawas, Andrew Lipsky, Seda Tolu, Jennifer E. Amengual, Barbara Pro, Melissa Beauchemin
DOI: 10.1080/10428194.2026.2678414
Cited by: 1
References: 30

Abstract

Dose intensity is critical in diffuse large B-cell lymphoma (DLBCL) but can be limited by toxicity risk. The influence of treatment intensity, illness burden, and socioeconomic status (SES) on survival in DLBCL has not been evaluated on a patient-level analysis. We performed a retrospective study of 344 patients with DLBCL from an urban academic cancer center; 55% received lower intensity treatment (average relative dose intensity [ARDI] of cyclophosphamide and doxorubicin

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment Multiple and Secondary Primary Cancers CNS Lymphoma Diagnosis and Treatment

Publication details

Journal / source
Leukemia & lymphoma/Leukemia and lymphoma
Publisher
Informa UK Limited
Volume
67
Issue
9
Pages
1953–1964
Publication date
7 June 2026
Language
EN